The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species

European Journal of Pharmacology

Volumn 633, Issue 1-3, 2010, Pages 85-92

  Guabiraba, Rodrigo ^a   Campanha Rodrigues, Ana Lucia ^a   Souza, Adriano L S ^a   Santiago, Helton C ^a   Lugnier, Claire ^b   Alvarez Leite, Jacqueline ^a   Lemos, Virginia S ^a   Teixeira, Mauro M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antioxidant; Dioclein; Flavonoid; Inflammation; PDE4 inhibitor; Reactive oxygen species

Indexed keywords

AUTACOID; BUTYLCRESOL; CXCL1 CHEMOKINE; DIOCLEIN; FLAVONOID; GAMMA INTERFERON; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PHOSPHODIESTERASE IV; REACTIVE OXYGEN METABOLITE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL FREE SYSTEM; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SUPERNATANT;

ANIMALS; ANTIOXIDANTS; BUTYLATED HYDROXYTOLUENE; CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; DRUG INTERACTIONS; FLAVANONES; FLAVONOIDS; FREE RADICAL SCAVENGERS; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST; ROLIPRAM;

EID: 77949915337     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.01.021     Document Type: Article

References (74)

1. Almeida A.P., Cortes S.F., Ferreira A.J., Lemos V.S. Increase on the coronary flow induced by dioclein in isolated rat heart. Life Sci. 2002, 70:1121-1128.
2. Alves-Filho J.C., de Freitas A., Spiller F., Souto F.O., Cunha F.Q. The Role of Neutrophils in Severe Sepsis. Shock 2008, 30(Suppl 1):3-9.
3. Au B.T., Teixeira M.M., Collins P.D., Williams T.J. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br. J. Pharmacol. 1998, 123:1260-1266.
4. Aviram M., Fuhrman B. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis 1998, 137 Suppl:S45-S50.
5. Baltus T., von Hundelshausen P., Mause S.F., Buhre W., Rossaint R., Weber C. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J. Leukoc. Biol. 2005, 78:435-441.
6. Banner K.H., Trevethick M.A. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol. Sci. 2004, 25:430-436.
7. Barnette M.S., Underwood D.C. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr. Opin. Pulm. Med. 2000, 6:164-169.
8. Bhattacharyya J., Batista J.S., Almeida R.N. Dioclein, a Flavanone from the Roots of Dioclea-Grandiflora. Phytochemistry 1995, 38:277-278.
9. Birrell M.A., McCluskie K., Wong S., Donnelly L.E., Barnes P.J., Belvisi M.G. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J. 2005, 19:840-841.
10. Bolger G.B., McPhee I., Houslay M.D. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J. Biol. Chem. 1996, 271:1065-1071.
11. Brown D.M., Donaldson K., Borm P.J., Schins R.P., Dehnhardt M., Gilmour P., Jimenez L.A., Stone V. Calcium and ROS-mediated activation of transcription factors and TNF-alpha cytokine gene expression in macrophages exposed to ultrafine particles. Am. J. Physiol., Lung Cell. Mol. Physiol. 2004, 286:L344-L353.
12. Brown D.M., Hutchison L., Donaldson K., MacKenzie S.J., Dick C.A., Stone V. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4. Toxicol. Lett. 2007, 168:1-6.
13. Chan E.L., Haudek S.B., Giroir B.P., Murphy J.T. Human coronary endothelial cell activation by endotoxin is characterized by NF-kappa B activation and TNF-alpha synthesis. Shock 2001, 16:349-354.
14. Cheng P.Y., Lee Y.M., Wu Y.S., Chang T.W., Jin J.S., Yen M.H. Protective effect of baicalein against endotoxic shock in rats in vivo and in vitro. Biochem. Pharmacol. 2007, 73:793-804.
15. Choi J.S., Chung H.Y., Kang S.S., Jung M.J., Kim J.W., No J.K., Jung H.A. The structure-activity relationship of flavonoids as scavengers of peroxynitrite. Phytother. Res. 2002, 16:232-235.
16. Choi J.M., Yoon B.S., Lee S.K., Hwang J.K., Ryang R. Antioxidant properties of neohesperidin dihydrochalcone: inhibition of hypochlorous acid-induced DNA strand breakage, protein degradation, and cell death. Biol. Pharm. Bull. 2007, 30:324-330.
17. Condos R., Raju B., Canova A., Zhao B.Y., Weiden M., Rom W.N., Pine R. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect. Immun. 2003, 71:2058-2064.
18. Cooper N., Teixeira M.M., Warneck J., Miotla J.M., Wills R.E., Macari D.M., Gristwood R.W., Hellewell P.G. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br. J. Pharmacol. 1999, 126:1863-1871.
19. Cortes S.F., Rezende B.A., Corriu C., Medeiros I.A., Teixeira M.M., Lopes M.J., Lemos V.S. Pharmacological evidence for the activation of potassium channels as the mechanism involved in the hypotensive and vasorelaxant effect of dioclein in rat small resistance arteries. Br. J. Pharmacol. 2001, 133:849-858.
20. Deng Y.M., Xie Q.M., Tang H.F., Sun J.G., Deng J.F., Chen J.Q., Yang S.Y. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma. Eur. J. Pharmacol. 2006, 547:125-135.
21. Dinarello C.A., Gelfand J.A., Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993, 269:1829-1835.
22. Drouet C., Shakhov A.N., Jongeneel C.V. Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J. Immunol. 1991, 147:1694-1700.
23. Es-Safi N.E., Ghidouche S., Ducrot P.H. Flavonoids: hemisynthesis, reactivity, characterization and free radical scavenging activity. Molecules 2007, 12:2228-2258.
24. Fromtling R.A., Abruzzo G.K. Chemiluminescence as a tool for the evaluation of antimicrobial agents: a review. Methods Find. Exp. Clin. Pharmacol. 1985, 7:493-500.
25. Geraets L., Haegens A., Brauers K., Haydock J.A., Vernooy J.H., Wouters E.F., Bast A., Hageman G.J. Inhibition of LPS-induced pulmonary inflammation by specific flavonoids. Biochem. Biophys. Res. Commun. 2009, 382:598-603.
26. Germain N., Corbel M., Belleguic C., Boichot E., Lagente V. Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells. Mediat. Inflamm. 2001, 10:117-123.
27. Giembycz M.A. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis. 2002, 57:48-64.
28. Goncalves R.L., Lugnier C., Keravis T., Lopes M.J., Fantini F.A., Schmitt M., Cortes S.F., Lemos V.S. The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. Eur. J. Pharmacol. 2009, 620:78-83.
29. Harkin D.W., Barros D'sa A.A., McCallion K., Hoper M., Halliday M.I., Campbell F.C. Circulating neutrophil priming and systemic inflammation in limb ischaemia-reperfusion injury. Int. Angiol. 2001, 20:78-89.
30. Heijnen C.G., Haenen G.R., van Acker F.A., van der Vijgh W.J., Bast A. Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups. Toxicol. In Vitro 2001, 15:3-6.
31. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993, 342:1007-1011.
32. Hirano M., Osada S., Aoki T., Hirai S., Hosaka M., Inoue J., Ohno S. MEK kinase is involved in tumor necrosis factor alpha-induced NF-kappaB activation and degradation of IkappaB-alpha. J. Biol. Chem. 1996, 271:13234-13238.
33. Jacob C., Szilagyi C., Allen J.M., Bertrand C., Lagente V. Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism. Br. J. Pharmacol. 2004, 143:257-268.
34. Jun C.D., Choi B.M., Hoon R., Um J.Y., Kwak H.J., Lee B.S., Paik S.G., Kim H.M., Chung H.T. Synergistic cooperation between phorbol ester and IFN-gamma for induction of nitric oxide synthesis in murine peritoneal macrophages. J. Immunol. 1994, 153:3684-3690.
35. Keravis T.M., Wells J.N., Hardman J.G. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim. Biophys. Acta 1980, 613:116-129.
36. Knekt P., Jarvinen R., Reunanen A., Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996, 312:478-481.
37. Ko W.C., Shih C.M., Lai Y.H., Chen J.H., Huang H.L. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem. Pharmacol. 2004, 68:2087-2094.
38. Koenen R.R., von Hundelshausen P., Nesmelova I.V., Zernecke A., Liehn E.A., Sarabi A., Kramp B.K., Piccinini A.M., Paludan S.R., Kowalska M.A., Kungl A.J., Hackeng T.M., Mayo K.H., Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 2009, 15:97-103.
39. Kuldo J.M., Westra J., Asgeirsdottir S.A., Kok R.J., Oosterhuis K., Rots M.G., Schouten J.P., Limburg P.C., Molema G. Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am. J. Physiol. Cell Physiol. 2005, 289:C1229-C1239.
40. Kuss H., Hoefgen N., Johanssen S., Kronbach T., Rundfeldt C. In vivo efficacy in airway disease models of N-(3, 5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyo xylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J. Pharmacol. Exp. Ther. 2003, 307:373-385.
41. Lemos V.S., Freitas M.R., Muller B., Lino Y.D., Queiroga C.E., Cortes S.F. Dioclein, a new nitric oxide- and endothelium-dependent vasodilator flavonoid. Eur. J. Pharmacol. 1999, 386:41-46.
42. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., Stoclet J.C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 1986, 35:1743-1751.
43. Matata B.M., Galinanes M. Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J. Biol. Chem. 2002, 277:2330-2335.
44. Maus U.A., Waelsch K., Kuziel W.A., Delbeck T., Mack M., Blackwell T.S., Christman J.W., Schlondorff D., Seeger W., Lohmeyer J. Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis. J. Immunol. 2003, 170:3273-3278.
45. Middleton E., Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52:673-751.
46. Miotla J.M., Teixeira M.M., Hellewell P.G. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am. J. Respir. Cell Mol. Biol. 1998, 18:411-420.
47. Molinari B.L., Tasat D.R., Palmieri M.A., O'Connor S.E., Cabrini R.L. Cell-based quantitative evaluation of the MTT assay. Anal. Quant. Cytol. Histol. 2003, 25:254-262.
48. Monaco C., Andreakos E., Young S., Feldmann M., Paleolog E. T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. J. Leukoc. Biol. 2002, 71:659-668.
49. Nichols M.R., Morimoto B.H. Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins. Mol. Pharmacol. 2000, 57:738-745.
50. Nishikawa M., Kakemizu N., Ito T., Kudo M., Kaneko T., Suzuki M., Udaka N., Ikeda H., Okubo T. Superoxide mediates cigarette smoke-induced infiltration of neutrophils into the airways through nuclear factor-kappaB activation and IL-8 mRNA expression in guinea pigs in vivo. Am. J. Respir. Cell Mol. Biol. 1999, 20:189-198.
51. Orallo F., Camina M., Alvarez E., Basaran H., Lugnier C. Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. Planta Med. 2005, 71:99-107.
52. Pavlovic R., Santaniello E. Peroxynitrite and nitrosoperoxycarbonate, a tightly connected oxidizing-nitrating couple in the reactive nitrogen-oxygen species family: new perspectives for protection from radical-promoted injury by flavonoids. J. Pharm. Pharmacol. 2007, 59:1687-1695.
53. Peluso M.R. Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp. Biol. Med. (Maywood) 2006, 231:1287-1299.
54. Podrez E.A., Schmitt D., Hoff H.F., Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 1999, 103:1547-1560.
55. Porath D., Riegger C., Drewe J., Schwager J. Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines. J. Pharmacol. Exp. Ther. 2005, 315:1172-1180.
56. Rahman I., Biswas S.K., Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 2006, 72:1439-1452.
57. Rezende B.A., Cortes S.F., De Sousa F.B., Lula I.S., Schmitt M., Sinisterra R.D., Lemos V.S. Complexation with beta-cyclodextrin confers oral activity on the flavonoid dioclein. Int. J. Pharm. 2009, 367:133-139.
58. Ribeiro S., Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol. Ther. 2005, 107:44-58.
59. Rice-Evans C., Miller N. Measurement of the antioxidant status of dietary constituents, low density lipoproteins and plasma. Prostaglandins Leukot. Essent. Fatty Acids 1997, 57:499-505.
60. Riou S., Mees B., Esposito B., Merval R., Vilar J., Stengel D., Ninio E., van Haperen R., de Crom R., Tedgui A., Lehoux S. High pressure promotes monocyte adhesion to the vascular wall. Circ. Res. 2007, 100:1226-1233.
61. Sanlioglu S., Williams C.M., Samavati L., Butler N.S., Wang G., McCray P.B., Ritchie T.C., Hunninghake G.W., Zandi E., Engelhardt J.F. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J. Biol. Chem. 2001, 276:30188-30198.
62. Silva P.M., Alves A.C., Serra M.F., Pires A.L., Silva J.P., Barreto E.O., Cordeiro R.S., Jose P.J., Teixeira M.M., Lagente V., Martins M.A. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br. J. Pharmacol. 2001, 134:283-294.
63. Souness J.E., Aldous D., Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000, 47:127-162.
64. Spearing P., Majetich G., Bhattacharyya J. Synthesis of (R, S)-dioclein, a bioactive flavanone from the root bark of Diocleia grandiflora. J. Nat. Prod. 1997, 60:399-400.
65. Stevenson D.E., Hurst R.D. Polyphenolic phytochemicals-just antioxidants or much more?. Cell. Mol. Life Sci. 2007, 64:2900-2916.
66. Teixeira M.M., Gristwood R.W., Cooper N., Hellewell P.G. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?. Trends Pharmacol. Sci. 1997, 18:164-171.
67. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 1998, 157:351-370.
68. Vianna H.R., Cortes S.F., Ferreira A.J., Capettini L.S., Schmitt M., Almeida A.P., Massensini A.R., Lemos V.S. Antiarrhythmogenic and antioxidant effect of the flavonoid dioclein in a model of cardiac ischemia/reperfusion. Planta Med. 2006, 72:300-303.
69. Vidal C., Gomez-Hernandez A., Sanchez-Galan E., Gonzalez A., Ortega L., Gomez-Gerique J.A., Tunon J., Egido J. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J. Pharmacol. Exp. Ther. 2007, 320:108-116.
70. Wilsson A., Lind S., Ohman L., Nilsdotter-Augustinsson A., Lundqvist-Setterud H. Apoptotic neutrophils containing Staphylococcus epidermidis stimulate macrophages to release the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-6. FEMS Immunol. Med. Microbiol. 2008, 53:126-135.
71. Wolfe K.L., Liu R.H. Structure-activity relationships of flavonoids in the cellular antioxidant activity assay. J. Agric. Food Chem. 2008, 56:8404-8411.
72. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., Achong M.K. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 1998, 101:311-320.
73. Zhu X., Liu Y., Liu S., Diao F., Xu R., Ni X. Lipopolysaccharide primes macrophages to increase nitric oxide production in response to Staphylococcus aureus. Immunol. Lett. 2007, 112:75-81.
74. Zielinska-Przyjemska M., Wiktorowicz K. An in vitro study of the protective effect of the flavonoid silydianin against reactive oxygen species. Phytother. Res. 2006, 20:115-119.